• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Biotronik touts FDA approval for next-gen heart devices at HRS 2012 | Regulatory Roundup

Biotronik touts FDA approval for next-gen heart devices at HRS 2012 | Regulatory Roundup

May 11, 2012 By MassDevice staff

MassDevice.com Regulatory Roundup

 Biotronik wins FDA aproval for next-gen heart failure devices

Biotronik landed FDA approval for its next-generation series of implantable heart devices, announcing the win at this year’s Heart Rhythm Society conference in Boston yesterday.

The Oregon-based device maker has touted approval for its Lumax 740, which Biotronik says features technology to provide better information to doctors monitoring a patient’s disease progression and includes Smart Detection technology designed to reduce the incidence of inappropriate shocks to the heart.

"In contrast to competitors, Biotronik’s Smart Detection continues to fully function even after a first therapy attempt, which allows the device to provide pain-free therapies without compromising specificity," according to a press release. "The ability to differentiate atrial from ventricular arrhythmias with high specificity reduces the risk for painful inappropriate shocks."

The company won CE Mark approval in the European Union in November 2011 for the Lumax 740 line with ProMRI technology, which it touted as the world’s first and only implantable defibrillator with clearance for use with MRIs.

Unnecessary-shock reduction appears to be the name of the game, with St. Jude Medical (NYSE:STJ) announcing earlier this week that it too landed FDA clearance for a new line of implantable heart devices featuring SecureSense and ShockGuard technology that aims to prevent unneeded therapy.

Medtronic (NYSE:MDT) yesterday unveiled results from a study demonstrating that delaying ICD shock therapy, effectively giving the device more time to diagnose an abnormal heart rhythm, can help reduce unnecessary shocks without increased risk to patients. Read more

 Loma Vista wins CE Mark for True ultra-precise balloon catheter for TAVI and BAVI

 Sorin Group lands FDA approval, announces launch of Paradym ICDs and CRT-Ds

 Interrad touts FDA clearance for new SecurAcath subcutaneous catheter securement device sizes

Filed Under: 510(k), News Well, Pre-Market Approval (PMA) Tagged With: Biotronik, Cardiac Rhythm Management, HRS 2012

More recent news

  • Neuronetics names Steven Pfanstiel chief financial officer
  • Medtronic to distribute Future Medical’s peripheral guidewires
  • AtriCure completes enrollment in stroke prevention trial
  • GT Medical raises $53M to support brain tumor treatment
  • Imperative Care, Proximie partner to develop surgical robot to treat stroke

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy